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Abstract The objective of the study is to validate intravas-
cular quantitative echogenicity as a surrogate for molecular
weight assessment of poly-l-lactide-acid (PLLA) bioresorb-
able scaffold (Absorb BVS, Abbott Vascular, Santa Clara,
California). We analyzed at 9 time points (from 1- to 42-month
follow-up) a population of 40 pigs that received 97 Absorb
scaffolds. The treated regions were analyzed by echogenicity
using adventitia as reference, and were categorized as more
(hyperechogenic or upperechogenic) or less bright (hypoe-
chogenic) than the reference. The volumes of echogenicity
categories were correlated with the measurements of molec-
ular weight (Mw) by gel permeation chromatography. Scaffold
struts appeared as high echogenic structures. The quantifica-
tion of grey level intensity in the scaffold-vessel compartment
had strong correlation with the scaffold Mw: hyperechoge-
nicity (correlation coefficient = 0.75; P \ 0.01), upperech-
ogenicity (correlation coefficient = 0.63; P \ 0.01) and
hyper ? upperechogenicity (correlation coefficient = 0.78;
P \ 0.01). In the linear regression, the R2 for high echoge-
nicity and Mw was 0.57 for the combination of hyper and upper
echogenicity. IVUS high intensity grey level quantification is
correlated to Absorb BVS residual molecular weight and can
be used as a surrogate for the monitoring of the degradation of
semi-crystalline polymers scaffolds.
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Abbreviations
IVUS Intravascular ultrasound
BRS Bioresorbable scaffolds
PLLA Poly-l-lactide-acid
PDLLA Poly-D, L-lactide
Mw Molecular weight
Absorb
BVS
Poly-l-lactide-acid everolimus eluting
bioresorbable scaffold
CAD Coronary artery disease
Impact on daily practice
Changes in bioresorbable vascular scaffolds (BRS), design
and compositions may affect their degradation and loss of
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biomechanical characteristics (with the risk of late recoil)
and may be associated with a second wave of arterial wall
inflammation. Therefore, studying the BRS degradation is
crucial to fully understand this technology. The present
work validates echogenicity as a surrogate for polylactide
scaffold degradation.
Introduction
Bioresorbable vascular scaffolds (BRS) are a novel
approach to the interventional treatment of coronary
artery disease (CAD), providing short-term vascular
scaffolding combined with drug-delivery capability. They
may offer potential advantages compared to metallic
drug-eluting stents (e.g. adaptive remodeling, restoration
of vasomotion and late luminal enlargement). The so
called 4th revolution in coronary artery disease revas-
cularization steered extensive scientific research in BRS
developments [1–3].
It has been shown that the designs and materials of BRS
platforms—either metallic or polymeric—influence the
resorption process [3–5]. Considering the variety of pos-
sible platforms, it is necessary to establish tools capable of
monitoring the degradation process and its correlated
mechanical characteristics.
Intravascular ultrasound-derived parameters have shown
to be useful to assess the BRS resorption of metallic and
polymeric scaffolds in humans [6–8]. One of the most
studied intravascular ultrasound (IVUS) techniques to
evaluate the resorption process is called differential ech-
ogenicity [8, 9]. This method consists in an automated and
quantitative three-dimensional analysis of coronary tissue
components scored for echogenicity using as reference the
mean level of the adventitia brightness [9] where scaffold
struts appear as bright hyperechogenic structures. In clin-
ical studies, a continuous decrease of echogenicity over
time has been shown in regions treated with BRS, being
putatively correlated to BRS degradation [7, 8]. However,
in serial human assessments, changes in the adventitia and
plaque-media compartment of the treated regions during
the follow-up period could possibly affect these interpre-
tations [10–14].
The objectives of the current study were: (1) to describe
a novel method of echogenicity for tissue analysis; (2) to
evaluate its reproducibility; and (3) to assess its aptitude to
assess the BRS degradation process through a direct cor-
relation with the molecular weight (Mw) in a preclinical
model using a drug-eluting poly-l-lactide-acid (PLLA) bi-
oresorbable scaffold (Absorb BVS, Abbott Vascular, Santa
Clara, California).
Methods
Study devices
The device used in the present preclinical study is the same
used in Cohort B of the ABSORB clinical trial [15, 16].
Absorb is a balloon-expandable BRS that consists of a
polymer backbone of Poly (L-lactide) (PLLA) coated with
a thin layer of a 1:1 mixture of Poly-D, L-lactide (PDLLA)
polymer with the antiproliferative drug everolimus to form
an amorphous drug-eluting coating matrix containing
100 lg of everolimus/cm2 of scaffold [17].
Experimental model
For validation purposes, we analyzed non-atherosclerotic
Yorkshire-Landrace swine which had been implanted with
Absorb BVS via femoral access according to published
procedures [18]. Absorb sizes were matched to the vessel
size at a target balloon-to-artery ratio of 1.0–1.1 (10 %
overstretch). Each animal received a single Absorb
(3.0 9 18 mm for 1-, 3-, and 6-month and 3.0x12 mm for
12- to 42-month) in 2 or 3 main coronary arteries. Forty
pigs (98 arteries) underwent IVUS acquisition and were
then euthanized at 1-month (n = 12 scaffolds), 3-(n = 12),
6-(n = 14), 12-(n = 12), 18-(n = 12), 24-(n = 12),
30-(n = 8), 36-(n = 8) or 42-months (n = 8). Each scaf-
fold had quantification of polymer degradation by gel
permeation chromatography (GPC). Experimental studies
received protocol approval from the institutional animal
care and use committee and were conducted in accordance
with American Heart Association guidelines for pre-clini-
cal research and the Guide for the Care and Use of Labo-
ratory Animals (National Institutes of Health 2010).
Gel permeation chromatography (GPC)
A previously reported GPC method, with a slightly modi-
fied sample extraction/purification process, was employed
to investigate the degradation of polymer over time by
evaluating the number-average molecular weight (Mn) of
polymer in the Absorb [19]. In the present method, the
extraction and purification of the polymer was repeated up
to five times until the polymer was fully extracted from the
tissue (i.e., the polymer signal in the last extract below the
quantitation limit of 0.3 mg/mL). The samples were ana-
lyzed prior at 1-, 3-, 6-, 12-, 18-, 24-, 30-, 36- and
42-months after implantation.
IVUS acquisition and analysis
All IVUS runs were acquired with 40 MHz mechanical
systems, using Galaxy V2.02 (Boston Scientific, MA,
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USA) at 1-, 3-, 6- and 12-month follow-ups and iLab at
18-, 24-, 30-, 36- and 42-month (Boston Scientific, MA,
USA). We used motorized pullback of 0.5 mm/s with a
frame rate of 30 frames/second. The regions of interest
were restrict to the scaffolded areas, identified by the first
and the last cross-sectional IVUS frame in which scaffold
struts could be identified and/or where the proximal or
distal metallic markers could be identified. Vessel, scaffold
and lumen contours were delimited every 0.5 mm blind to
molecular weight results. We analysed four compartments
by IVUS: the luminal, scaffold, vessel and the neointimal
volume (vessel volume-lumen volume). The scaffold was
delineated semiautomatically at the luminal leading edge
of the struts and the lumen was delineated at the inner
detectable tissue (Fig. 1).
To evaluate inter-observer reproducibility, 2 readers
(C.C. and Y.I.) independently analyzed 30 segments ran-
domly selected from the total number of the investigated
segments. To determine intra-observer reproducibility, one
reader (C.C.) analyzed these segments twice, with the
second reading occurring 3 months later. The inter- and
intra-observer reproducibility were good according to the
conventional norms [20] (hyperechogenicity inter-observer
interclass correlation coefficient [ICC] = 0.80, intra-
observer ICC = 0.95; hypoechogenicity: inter-observer
ICC = 0.78, intra-observer ICC = 0.97; upperechogenici-
ty: inter-observer ICC = 0.92, intra-observer ICC = 0.97)
(Supplementary material).
Automatic quantitative echogenicity analysis
The principle of echogenicity has been previously descri-
bed elsewhere [9, 21, 22]. Echogenicity aims to classify the
vessel wall components located between the luminal
boundary and the external elastic membrane (EEM) into
categories based on their grey-level intensity in B-mode
IVUS images rather than based on radiofrequency ultra-
sound signal analysis [23–26] (Fig. 1). Here we quantified
5 tissue types: hypoechogenic, hyperechogenic, calcified,
upperechogenic and unknown.
Comparison with the adventitia allows for normaliza-
tion with respect to transducer variability, gain settings
and across populations [21]. However, in the analysis of
atherosclerotic tissue, the adventitia can be partially
obscured or darkened as a result of the guide-wire
shadowing or the presence of dense tissue (e.g. calcium)
which reduces the average grey-level values of the
adventitia. Therefore, these parts need to be excluded
from the reference adventitial area. To determine the
reference adventitia area in each frame, the full adven-
titial area located just outside the EEM is first deter-
mined based on a minimum (0.01 mm) and maximum
(0.21 mm) distance from the EEM contour (Fig. 1). To
remove the low echogenic parts of the adventitia an
adaptive threshold value for the entire adventitia area is
determined based on Otsu’s method [27]. Otsu’s method
is a classic automatic non-parametric threshold selection
method which maximizes the between-class variance.
Next, the adventitial area is divided into 2-degree wide
sectors. If more than half of the pixels inside of a sector
is below the adaptive threshold, the sector is excluded
from the reference adventitia area. Finally, the histo-
grams of the reference adventitial areas of the individual
frames are combined into a global adventitia grey-level
intensity histogram and the median value is computed as
a threshold. Cross-section pixels with an intensity lower
than the median value are classified as hypoechogenic,
pixels with an intensity higher than the median value
threshold are classified as hyperechogenic.
Calcified plaque is typically identified in B-mode
IVUS images as a highly echogenic area creating an
acoustic shadow [21]. To determine the high-intensity
grey-level threshold for highly echogenic components we
use the adaptive threshold selection method described in
[28]. First Otsu’s method is applied to the entire grey-
level histogram of an image resulting in an optimal
threshold value. In the next 2 iterations, Otsu’s method is
applied to the histogram of all intensities above the
threshold found in the previous step. Next, we apply an
in-house developed acoustic shadow detection algorithm.
Highly echogenic areas with a grey-level intensity higher
than the high-intensity threshold but without acoustic
shadow behind them are classified as upperechogenic,
while highly echogenic areas with acoustic shadow are
classified as calcified and the shadow itself is classified
as unknown. The entire method has been implemented
and tested in QCU-CMS-Research v4.69 (research ver-
sion of QIvus, developed by the Leiden University
Medical Center) [29].
Data analysis
Continuous variables are presented as mean ± SD or
medians (interquartile range). The ANOVA test was used
to compare continuous variables. As we had different
scaffold lengths we normalized all measurements by the
mean length for all pigs as described previously [30].
This adjusts for differing segment lengths across animals,
thereby providing equal weighting of each individual in
the calculation of echogenicity volumes. The residual
scaffold molecular weight by GPC was compared to the
echogenicity findings and the correlation coefficient was
used as a measure of the degree of relationship (Pear-
son’s correlation coefficient). A linear regression was
used to evaluate if hyper and/or upperechogenicity were
able to predict the residual molecular weight. A
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Fig. 1 Differential
echogenicity methodology.
a The first step was to determine
the lumen-scaffold and scaffold-
vessel compartments by
defining the vessel, lumen and
luminal scaffold contours in
every 0.5 mm. After guidewire
masking, the software identifies
the adventitia as a ring between
0.01 and 0.21 mm outside
vessel contours. b However, if
the software uses as reference
the whole layer around the
vessel contour, it will include
low intensity structures (e.g.,
pericardium, side branches, low
attenuated tissues, etc.) resulting
in a histogram with a non-
normal distribution (right
panel). c The present software
detects automatically high
signal adventitia as reference,
excluding low intensity
structures (arrow heads). The
right panel shows that the
combination of high signal
adventitia in all frames obtains a
bell shaped normally distributed
histogram. The yellow line
represents the referential
adventitial median value. d The
color legend of each
echogenicity classification is
provided. As we used a non-
atherosclerotic porcine model
there was no calcification and
unknown tissue. Nevertheless,
the present software is able to
detect theses tissues
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hierarchical cluster analysis using Ward’s method
(Squared Euclidean distance) was applied for
hyper ? upperechogenicity and hypoechogenicity vol-
umes. The differences were regarded significant when
P \ 0.05 (two-tailed). SPSS version 21.0 (SPSS Inc.,
Chicago, Illinois) was used for all statistical analyses.
Results
The main grey scale IVUS volumetric findings are shown
in Fig. 2 and the comparisons between each group are
given in the supplementary material (Tables 2-5). The
mean scaffold length was 16.5 mm. Compared with
1-month follow-up, the vessel, scaffold and lumen volumes
had a trend to be larger after 18-month follow-up. These
three aforementioned volumes were significantly larger at
36- and 42-month. Additionally, the neointima had the
biggest volume at 1-month follow-up, being similar among
groups thereafter (Fig. 3).
Differential echogenicity and molecular weight
Table 1 summarizes the main findings on differential
echogenicity and mean Mw at each time point. The highest
total hypoechogenicity volume was found at 1-month fol-
low-up, the time point with also the highest neointimal
hyperplasia as aforementioned. The lumen-scaffold com-
partment had an increase in hyper ? upperechogenic vol-
umes up to 12-month and subsequently a decrease until
42-month. Using the as reference the 1-month group, the
hyper ? upperechogenic decreased significantly in the
scaffold vessel compartment after 12 months (supplemen-
tary material).
The GPC results indicated a continuous decrease in
molecular weight over time. The rate of reduction was
slower during the first 6-months of scaffold implantation
followed by a more rapid decline thereafter, being fully
resorbed 36-months after implantation (Fig. 2).
To validate the scaffold degradation by echogenicity we
took into consideration the hyper- and upperechogenicity in
Fig. 2 Grey Scale intravascular ultrasound volumetric findings at different time points. a Vessel volume; b Lumen Volume; c Scaffold Volume
and d Neointimal Volume. Values are median and interquartile range
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the scaffold-vessel compartment (Fig. 1). As shown in
Table 1, the earlier IVUS were more likely to present higher
grey-level intensity (hyper ? upperechogenicity). The scaf-
fold-vessel hyperechogenicity (Pearson correlation coeffi-
cient = 0.75; P \ 0.01), upperechogenicity (Pearson
correlation coefficient = 0.63; P \ 0.01) and hyper ? up-
perechogenicity (Pearson correlation coefficient = 0.78;
P \ 0.01) had strong correlation with the scaffold molecular
weight. As shown in Fig. 4, in linear regression, the best
correlation found in linear regression model for molecular
weight was scaffold-vessel hyper ? upperechogenicity (R
squared = 0.57; P \ 0.01); i.e., all grey-level intensity
higher than median adventitia in the scaffold-vessel com-
partment should be considered for monitoring the degrada-
tion process of this semi-crystalline polymers scaffold. Post-
Hoc comparisons between each group are given in the sup-
plementary material (Tables 6-8).
Additionally, a cluster analysis was run for scaffold-
vessel hyper ? upperechogenicity and hypoechogenicity.
It produced five clusters, among which the variables were
significantly different in the main (Fig. 5). The comparison
among clusters of hyper ? upperechogenicity showed a
clear positive association scaffold-vessel hyper ? upper-
echogenicity and molecular weight (Fig. 5).
Fig. 3 IVUS echogenicity
analysis at 1- (a), 18- (b) and
42-month (c). The high
echogenic (including
hyper = light green and
upper = light blue) parameters
decrease over time. d Gel
permeation chromatography
(GPC) for the assessment of
degradation of Absorb showing
the in vivo degradation of
polymer of Absorb over time
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Discussion
In the present study, using IVUS grey scale derived
parameters we attempted to assess the degradation process
of the Absorb poly-L-lactide bioresorbable everolimus-
eluting scaffold at multiple time points in a porcine model.
The major findings of this study can be summarized as
follows: (1) hyperechogenic and upperechogenic thresh-
olds had strong and positive correlations with the scaffold
molecular weight assessment; (2) the combination of hyper
and upperechogenicity could be used as a surrogate for the
chromatographic assessment of scaffold molecular weight
and (3) echogenicity demonstrated good inter- and intra-
observer reproducibility (Supplementary Material).
The present manuscript describes a new software
designed to assess the differential echogenicity and, for the
first time, ascertained the correlation between IVUS grey
scale intensities and quantitative assessment of Mw by
GPC. The first novelty is that it was not necessary to use
ECG gating and therefore, it is not needed a dedicated
IVUS console or post-processing correction. The robust-
ness of this method and the aforementioned good repro-
ducibility demonstrate, for the first time, good correlation
of echogenicity with the degradation of the scaffold with-
out being mandatory correction for motion artifacts [30].
Image resolution can be defined as the capability of
making distinguishable the individual parts of an object.
Therefore, the use of 40 MHz IVUS catheter in the present
study has potential to be more precise to detect scaffold
degradation than the previous methodology with the
20 MHz ultrasound [7, 31]. Ultrasound at a center fre-
quency of 10 MHz has demonstrated to detect decline in
the acoustic impedance of PLA when molecular weight
varied from 60 to 24 kDa, but further decrease in molecular
weight to 15 kDa did not result in discernible change [32].
In the present study, working with the higher resolution of
the 40 MHz IVUS catheter, we were able to detect acoustic
differences in 150 m thick samples degrading from *100
to \4 kDa.
The use of ultrasound to monitor the degradation
process of polymers has been initially proposed with a
wave pulse-echo method in an in vitro essay [31]. Wu
succeeded to monitor by ultrasound the degradation
process of three biodegradable polymers: poly(glycolic
acid) (PGA), poly(L-lactic acid) (PLLA) and 50:50
poly(D, L-lactide-co-glycolide) (PDLLG) [33]. Another
IVUS based approach to detect the resorption process in
human is virtual histology [6]. The spectral analysis of
the raw backscattered ultrasound misrepresents polymeric
struts as dense calcium (DC) and necrotic core (NC). As
these parameters are shown to decrease over time after
implantation, they have been correlated putatively with
resorption [6, 16, 34, 35].T
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Fig. 4 Linear regressions between molecular weight and echogenicity derived parameters in the scaffold-vessel compartment
Fig. 5 A hierarchical cluster analysis labeled by animal was run for
scaffold-vessel hyper ? upperechogenicity and hypoechogenicity.
Cluster 2 and 3 had similar hyper ? upperechogenicity but statisti-
cally significant greater hypoechogenicity volumes in the cluster 2.
Cluster 3 and 5 had similar hypoechogenicity but markedly higher
hyper ? upperechogenicity volumes in cluster 5. There was a clear
positive association between scaffold-vessel hyper ? upperechoge-
nicity and molecular weight. The sample sizes are number of
scaffolds included in each pig cluster. The values are mean ± stan-
dard deviation and the errors bars are 95 % confidence interval
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Previously, echogenicity has been used to assess paired
serial acoustic properties of coronary plaques in BRS-
treated segments in the clinical setting [7, 8, 35]. It has
been shown that these segments had an increase in hy-
perechogenic tissue after implantation which decreased
over time [7, 8, 35]. The aforementioned methodology
succeeds to document the progressive decrease of high
intensity grey level tissues in both metallic and polymeric
BRS [8, 35].
However, until now, the link between echogenicity and
the degradation process has been hypothetically assumed.
The pending question was whether temporal plaque chan-
ges could interfere with the multistage degradation of the
polymer and confound the echogenicity analysis. It has
been shown that coronary atherosclerosis is a dynamic
phenomenon and numerous factors can influence the ath-
erosclerotic changes as detected by IVUS-derived param-
eters. For instance, statin treatment may reduce the
percentage lipid volume index over time [13] and may
increase the calcified plaque component [11]. Additionally,
there is a significant decrease in NC (16 %) and DC (30 %)
content in coronary plaque located behind the struts of the
everolimus-eluting bioresorbable vascular scaffold [36].
All the above-mentioned confounding factors might influ-
ence the acoustic properties in the lumen-vessel compart-
ment and hinder the clinical relevance of echogenicity for
BRS degradation assessment.
As we have used a porcine non-atherosclerotic model,
we did not have the confounding presence of coronary
artery disease, thus enabling the evaluation of Poly-L-
Lactide’s echogenic characteristics over time. Hyperecho-
genic, upperechogenenic and hyper ? upperechogenic
tissues had strong and positive correlations between ech-
ogenicity and the degradation process. Echogenicity is
determined by the difference in acoustic impedance
between two mediums, which is proportional to density and
acoustic velocity. The acoustic velocity is proportional to
the square root of the stiffness (bulk and shear moduli).
Many factors impact the stiffness of PLA, including
molecular weight, polydispersity, crystallinity, orientation
of crystalline microstructure, and other environmental
conditions [37]. As a result, one would expect to change
the impedance of PLA as it degrades and molecular weight
to have a generalized relationship to this decline.
Qualitatively, the correlation was however not perfectly
linear. For instance, at 1-month the combination hyper ?
upper tended (without statistical significance; Table 6, sup-
plementary material), in average, to be lower than at
3-months whereas the molecular weight had a continuous
decrease in the same period. From the ultrasonic point of
view, the significantly higher neointimal hyperplasia (Fig. 2)
at 1-month might have affected the ultrasound penetration
and therefore the echogenicity interpretation. Additionally,
the scaffold-vessel hyper ? upperechogenicity at
30-months was numerically comparable to that at 18-month.
However, the degradation process may be influenced by
individual biological factors and it has to be emphasized that
these assessments were not serial. However, we showed a
consistent individual positive correlation between the
molecular weight and echogenicity (Figs. 4 and 5).
Limitations
Arteries used for molecular weight assessment could not be
evaluated histologically. Therefore, changes in the
observed echogenicity (both lumen-scaffold and scaffold-
vessel) could not be related to the histologic changes over
time [19, 38]. As this study has been performed in a non-
atherosclerotic model, it should be acknowledged that the
rate of degradation has not been confirmed in atheroscle-
rotic coronary arteries. However, as the degradation of
PLLA is a hydrolytically driven and not enzymatically
driven process, it is expected that the rates would be largely
equivalent.
We could not test the reproducibility of the echogenicity
IVUS findings in the two different consoles. However as we
worked at the same ultrasound frequency (40 MHz) and the
tissue classifications were normalized by the individual
adventitia grey scale intensity we could show a robust cor-
relation between scaffold degradation and high echogenic
parameters. It has been shown that the comparison with the
adventitia allows for normalization with respect to trans-
ducer variability, gain settings and across populations [21].
The changes in vessel, lumen, scaffold and neointima
volumes over time are in line with the serial IVUS findings
in the pre-clinical model and clinical setting showing
progressive increase in vessel, lumen area and scaffold area
[16, 18, 39, 40]. However, in the porcine model the somatic
growth can influence our findings [39]. As we do not have
the IVUS at baseline we could not normalize these geo-
metrical changes for the increase in the reference vessel
size. Nevertheless, this information has been described in
the literature and are beyond the main scope of the current
manuscript.
Conclusion
IVUS high intensity grey level quantification is correlated
to Absorb scaffold residual molecular weight assessment.
Echogenicity is a reproducible technique which could be
considered as a surrogate assessment of polylactide
molecular weight decrease as assessed by chromatography
and allows for monitoring of the degradation of semi-
crystalline polymeric scaffolds.
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